



Antidepressant Drug

Guest Editor:

Dr. Paulina Misztak

Department of Medicine and
Surgery, University of Milano-
Bicocca, 20900 Monza, Italy

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editor

Antidepressants (Ads) mostly work by increasing extrasynaptic monoamine levels in the brain, which leads to many side effects on the peripheral nervous system. Moreover, ADs have a delayed onset of action even after weeks of treatment. Therefore, new rapid-action antidepressants, among them ketamine and NMDA antagonists, are being intensively studied. Nowadays, antidepressant drugs are divided into five classes: SSRIs, SNRIs, TCAs, MAOIs and atypical antidepressants with unique mechanisms of action. Furthermore, natural antidepressants such as omega-3-fatty acids or exercise, which can supplement antidepressant therapy, are gaining traction. Therefore, the development of new drugs and methods for depression treatment is critical.

In this Special Issue, we aim to present well-known and new therapeutic agents and strategy for depression treatment. We will be focusing on traditional treatments and novel antidepressant molecules, such as peptides or cannabinoids, as well nutrition supplementation, which can be important for MDD treatment. In this Special Issue, we want to expand the knowledge on antidepressant drugs and their mechanism of action.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com